Increasing Prevalence of Chronic Diseases driving the in Bioprocess Technology Market growth during 2023–2028

According to our latest study on “Bioprocess Technology Market Size and Forecast to 2028 – COVID-19 Impact and Global Analysis – Type, Modality, and End User," the bioprocess technology market size is expected to grow from US$ 30,897.52 million in 2022 and is expected to reach a value of US$ 77,090.05 million by 2028; it is anticipated to record a CAGR of 16.8% from 2023 to 2028. The report highlights the key factors driving the bioprocess technology market growth and prominent players with their developments in the bioprocess technology market.

The unprecedented rate of aging population and extended periods of physical inactivity are boosting the prevalence lifestyle disorders, such as obesity and diabetes. Genes can cause conditions such as cardiovascular disease (CVDs), diabetes, obesity, Alzheimer's disease, and depression.

According to the National Council on Aging, Inc., 80% of adults (aged 65 and more) are reported to suffer from at least one chronic condition in their lifetime, while 68% have two or more. According to the Centers for Disease Control and Prevention (CDC), nearly 6 of 10 people in the US suffered from at least one serious disease, and 4 of 10 people have had two or more chronic conditions in 2020.

CVDs, such as angina pectoris, atherosclerosis, and acute myocardial infarction, caused due to hectic lifestyles are significant causes of mortality across the world. As per the World Health Organization data, CVDs are leading cause of death globally, recording 17.9 million deaths each year. Diabetes is a life-threatening chronic disease with no functional cure. Diabetes of all types can cause various complications in different body parts, thereby increasing the overall risk of death. Heart attack, kidney failure, stroke, leg amputation, nerve damage, and vision loss are among the major complications associated with diabetes. According to the International Diabetes Federation (IDF), diabetic cases in North America are expected to reach 62 million by 2045 from 46 million in 2017. The data further reported that 425 million people suffered from diabetes in 2017, and the count is likely to reach 629 million by 2045 worldwide. The disease prevalence is likely to increase by about 35% during the forecast period. 

Recognition of biosimilars as efficacious and safe agents by patients, specialists, primary care clinicians, and other healthcare professionals is propelling its demand. Biosimilars have proven to improve the quality of life for millions of patients. They are effective and cost-effective options in treating many diseases, including chronic skin conditions (such as psoriasis, Atopic Dermatitis), bowel diseases (such as Crohn’s disease, irritable bowel syndrome, and colitis), diabetes, autoimmune disease, cancer, kidney conditions, and arthritis. Biosimilar developers are adopting advanced bioprocessing technologies to achieve lower manufacturing costs, an important factor determining final consumer prices. Nearly all biosimilar developers are using modern, often cutting-edge bioprocessing techniques. This indicates that a majority of biosimilars are being developed using single use (disposed of after-use) bioprocessing systems.

With the growing prevalence of chronic diseases, the demand for biosimilars to treat life-threatening illnesses is spurring, thereby propelling the demand for bioprocessing technologies.

Based on modality, the bioprocess technology market is bifurcated into single use and multiple use. The single use segment held the largest share of the bioprocess technology market in 2022 and multiple use is expected to grow at the highest CAGR during the forecast period.

Merck KGaA, Sartorius AG, Thermo Fisher Scientific Inc, Corning Inc, STAMM Biotech, Lonza Group AG, Eppendorf SE, Repligen Corp, Danaher Corp, BioPharma Dynamics are among the leading companies operating in the global bioprocess technology market.

Companies operating in the bioprocess technology market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the bioprocess technology market. These growth strategies allow the bioprocess technology market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall bioprocess technology market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

A few of the significant developments by key market players are listed below.

• In June 2022, Merck has entered a collaboration with Agilent Technologies to advance Process Analytical Technologies (PAT). PAT, which is strongly encouraged by global regulatory authorities, is a key enabler for real-time release and Bioprocessing 4.0.
• In March 2020, Sartorius launched BIOSTAT STR Generation 3 single-use bioreactor and BIOBRAIN automation platform to introduce innovations that will change the field of biopharmaceutical process development and manufacturing. Biostat STR simplifies biologics production.
• In April 2022, Thermo Fisher Scientific opens its new single-use technology manufacturing site in Ogden, Utah. The state-of-the-art facility creates additional capacity to produce the high-quality technology and materials needed for the development of new vaccines and breakthrough therapies. The US$44 million facility is part of Thermo Fisher's US$650 million multi-year investment. The Ogden site is a 55,000-square-foot facility that will manufacture highly customizable bioprocess container (BPC) systems.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com